OptiNose (NASDAQ:OPTN) Price Target Raised to $18.00

OptiNose (NASDAQ:OPTN) had its target price boosted by HC Wainwright from $5.00 to $18.00 in a research report report published on Friday morning, MarketBeat Ratings reports. HC Wainwright currently has a buy rating on the stock. HC Wainwright also issued estimates for OptiNose’s FY2029 earnings at $1.41 EPS.

Separately, Piper Sandler lowered their price target on shares of OptiNose from $45.00 to $15.00 and set an “overweight” rating on the stock in a report on Wednesday, November 13th.

OptiNose Trading Down 3.0 %

NASDAQ:OPTN opened at $6.50 on Friday. The stock has a market capitalization of $65.39 million, a PE ratio of -23.21 and a beta of -0.15. The firm’s 50 day moving average is $7.81 and its 200 day moving average is $11.82. OptiNose has a 12 month low of $4.82 and a 12 month high of $31.50.

Institutional Investors Weigh In On OptiNose

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Geode Capital Management LLC raised its holdings in OptiNose by 33.7% during the 3rd quarter. Geode Capital Management LLC now owns 1,298,333 shares of the company’s stock valued at $870,000 after acquiring an additional 326,918 shares during the period. State Street Corp raised its holdings in OptiNose by 14.2% during the 3rd quarter. State Street Corp now owns 341,303 shares of the company’s stock valued at $229,000 after acquiring an additional 42,500 shares during the period. Stonepine Capital Management LLC raised its holdings in OptiNose by 142.1% during the 3rd quarter. Stonepine Capital Management LLC now owns 5,688,590 shares of the company’s stock valued at $3,811,000 after acquiring an additional 3,338,580 shares during the period. FMR LLC raised its holdings in OptiNose by 3.2% during the 3rd quarter. FMR LLC now owns 16,541,849 shares of the company’s stock valued at $11,083,000 after acquiring an additional 518,610 shares during the period. Finally, Massachusetts Financial Services Co. MA raised its holdings in OptiNose by 5.3% during the 3rd quarter. Massachusetts Financial Services Co. MA now owns 3,075,638 shares of the company’s stock valued at $2,061,000 after acquiring an additional 155,329 shares during the period. Institutional investors own 85.60% of the company’s stock.

About OptiNose

OptiNose, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase IIIb clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device.